InvestSMART

ImpediMed Limited (ASX:IPD)

ALERT: Price-sensitive ASX Announcement for IPD
Current share price for IPD : $0.005 -0.032 (-86.49%)+
Announcement
Release
2 Oct 2025 8:39AM
Price at Release
$0.037
Full Release
download
Summary
ImpediMed Limited announced that a major US health insurer has issued positive coverage for the use of bioimpedance spectroscopy for lymphedema assessment, significantly expanding insurance reimbursement for its SOZO® Digital Health Platform. This expansion covers an additional 16 million lives, bringing total coverage to over 301 million in the US, with 86% of patients now reimbursed for this testing. The recognition of bioimpedance spectroscopy as medically necessary marks a critical step in offering earlier detection and intervention of lymphedema, particularly for breast cancer survivors. This development enhances the feasibility of implementing SOZO-based prevention programs in hospitals and aligns with ImpediMed's mission to provide access to surveillance for at-risk cancer patients.
Key Points
  • Major US health insurer recognizes bioimpedance spectroscopy (BIS) as medically necessary for lymphedema assessment.
  • Coverage expansion to include 16 million additional covered lives, increasing total to over 301 million.
  • SOZO® Digital Health Platform by ImpediMed is now reimbursed across 86% of the US.
  • Coverage takes five states above 80% coverage, with Texas and Illinois among them.
  • ImpediMed’s technology allows for early detection and intervention of lymphedema to prevent progression and improve quality of life.
  • Positive coverage from a major insurer enhances commercial feasibility of SOZO in hospital systems.
  • ImpediMed aims to ensure access to SOZO surveillance for all cancer patients at risk of lymphedema.
  • Dr. Parmjot Bains emphasizes the significance of insurance recognition for BIS and its impact on patient care.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.